HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction.

Abstract
While secretory-leukocyte-protease-inhibitor (SLPI) may promote skin wound healing, its role in infarct healing after reperfused myocardial infarction (RMI) remains unclear. Short-term intravenous angiotensin II (AngII) receptor blocker therapy with candesartan (CN) attenuates increased SLPI and markers of early matrix/left ventricular (LV) in acute RMI. To determine whether reducing effects of AngII with CN or the vasopeptidase inhibitor omapatrilat (OMA) during the healing phase after RMI attenuates SLPI and other mediators of healing and matrix/LV remodeling, we measured these in Sprague-Dawley rats randomized to oral placebo, CN (30 mg/kg/day) or OMA (10 mg/kg/day) therapy during healing between days 2 and 23 after RMI and sham. On day-25, RMI-placebo showed significant LV remodeling, systolic/diastolic dysfunction and impaired passive compliance, and ischemic zone increases in SLPI, secreted-protein-acidic-and-rich-in-cysteine (SPARC) and osteopontin (OPN) mRNA and protein. In addition, metalloproteinase (MMP)-9 and -2, a-disintegrin-and-metalloproteinase (ADAM)-10 and -17, inducible-nitric-oxide-synthase (iNOS), pro-inflammatory cytokines interleukin (IL)-6, and tumor necrosis factor-α, transforming growth factor (TGF)-β(1) and its signaling molecule p-Smad-2, myeloperoxidase (MPO), AngII, MPO-positive granulocytes, MAC387-positive macrophages and monocytes, scar collagens, cardiomyocyte and fibroblast apoptosis, and microvascular no-reflow also increased whereas anti-inflammatory cytokine IL-10 decreased. Both CN and OMA attenuated all the changes except IL-10, which normalized. Thus, CN or OMA treatment during healing after RMI results in attenuation of SLPI as well as tissue AngII and mediators of inflammation and matrix/LV remodeling including SPARC, OPN, and ADAMs. Whether increasing SLPI on top of background AngII inhibition or therapy such as CN or OMA might produce added remodeling benefit needs study.
AuthorsAriv Palaniyappan, Richard R E Uwiera, Halliday Idikio, Vijay Menon, Catherine Jugdutt, Bodh I Jugdutt
JournalMolecular and cellular biochemistry (Mol Cell Biochem) Vol. 376 Issue 1-2 Pg. 175-88 (Apr 2013) ISSN: 1573-4919 [Electronic] Netherlands
PMID23361363 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Osteonectin
  • Pyridines
  • Secretory Leukocyte Peptidase Inhibitor
  • Slpi protein, rat
  • Tetrazoles
  • Thiazepines
  • Angiotensin II
  • omapatrilat
  • Collagen
  • candesartan
Topics
  • Angiotensin II (metabolism)
  • Angiotensin II Type 1 Receptor Blockers (pharmacology)
  • Animals
  • Apoptosis (drug effects)
  • Benzimidazoles (pharmacology)
  • Collagen (metabolism)
  • Male
  • Myocardial Infarction (drug therapy, metabolism, mortality, physiopathology)
  • Myocardial Reperfusion
  • Osteonectin (metabolism)
  • Pyridines (pharmacology)
  • Rats, Sprague-Dawley
  • Secretory Leukocyte Peptidase Inhibitor (metabolism)
  • Tetrazoles (pharmacology)
  • Thiazepines (pharmacology)
  • Ventricular Remodeling (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: